Tislelizumab plus chemo slows advanced squamous NSCLC
UK eyes mass testing as it takes next steps out of lockdown
5 April 2021Going deep: Artificial intelligence improves accuracy of breast ultrasound diagnoses
5 April 2021Tislelizumab plus chemo slows advanced squamous NSCLC
(HealthDay)—For patients with advanced squamous non-small cell lung cancer (sq- NSCLC), adding tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS), according to a study published online April 1 in JAMA Oncology.
